Sudden death and use of stimulant medications in youths.

OBJECTIVE The authors sought to determine whether a significant association exists between the use of stimulants and the rare event of sudden unexplained death in children and adolescents. METHOD A matched case-control design was performed. Mortality data from 1985-1996 state vital statistics were used to identify 564 cases of sudden death occurring at ages 7 through 19 years across the United States along with a matched group of 564 young people who died as passengers in motor vehicle traffic accidents. The primary exposure measure was the presence of amphetamine, dextroamphetamine, methamphetamine, or methylphenidate according to informant reports or as noted in medical examiner records, toxicology results, or death certificates. RESULTS In 10 (1.8%) of the sudden unexplained deaths it was determined that the youths were taking stimulants, specifically methylphenidate; in contrast, use of stimulants was found in only two subjects in the motor vehicle accident comparison group (0.4%), with only one involving methylphenidate use. A significant association of stimulant use with sudden unexplained death emerged from the primary analysis, which was based on exact conditional logistic regression (odds ratio=7.4, 95% CI=1.4 to 74.9). A comprehensive series of sensitivity analyses yielded qualitatively similar findings. CONCLUSIONS This case-control study provides support for an association between the use of stimulants and sudden unexplained death among children and adolescents. Although sudden unexplained death is a rare event, this finding should be considered in the context of other data about the risk and benefit of stimulants in medical treatment.

[1]  M. W. Daly,et al.  Cardiac Arrest with Pulseless Electrical Activity Associated with Methylphenidate in an Adolescent with Normal Baseline Echocardiogram , 2008, Pharmacotherapy.

[2]  Sander Greenland,et al.  Case–Control Studies , 2008 .

[3]  K. Towbin Paying attention to stimulants: height, weight, and cardiovascular monitoring in clinical practice. , 2008, Journal of the American Academy of Child and Adolescent Psychiatry.

[4]  R. Friedman,et al.  Cardiovascular Monitoring and Stimulant Drugs for Attention-Deficit/Hyperactivity Disorder , 2008, Pediatrics.

[5]  S. Berger,et al.  Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: A scientific statement from the American Heart Association Council on cardiovascular disease in the Young Congenital Cardiac Defects Committee and the Council On Cardiovascular Nursing , 2008 .

[6]  J. Shuster,et al.  Cardiac Safety of Central Nervous System Stimulants in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder , 2007, Pediatrics.

[7]  J. Biederman,et al.  Stimulants and Sudden Death: What Is a Physician to Do? , 2006, Pediatrics.

[8]  G. Norquist,et al.  Recent trends in stimulant medication use among U.S. children. , 2006, The American journal of psychiatry.

[9]  A. Awasthi,et al.  Acute myocardial infarction in a young male on methylphenidate, bupropion, and erythromycin. , 2005, Journal of child and adolescent psychopharmacology.

[10]  P. Gandhi,et al.  Myocardial infarction in an adolescent taking Adderall. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[11]  P. Kirshbom,et al.  Late neurodevelopmental outcome after repair of total anomalous pulmonary venous connection. , 2005, The Journal of thoracic and cardiovascular surgery.

[12]  E. Hunkeler,et al.  Trends in use of antidepressants, lithium, and anticonvulsants in Kaiser Permanente-insured youths, 1994-2003. , 2005, Journal of child and adolescent psychopharmacology.

[13]  S. Berger,et al.  Sudden cardiac death in children and adolescents: introduction and overview. , 2004, Pediatric clinics of North America.

[14]  Abraham Weizman,et al.  Methylphenidate treatment for attention-deficit/hyperactivity disorder in children and adolescents with velocardiofacial syndrome: an open-label study. , 2003, The Journal of clinical psychiatry.

[15]  Arvind K. Shah,et al.  Causes of death in sickle cell disease: an autopsy study , 2003, British journal of haematology.

[16]  M. Olfson,et al.  National trends in the treatment of attention deficit hyperactivity disorder. , 2003, The American journal of psychiatry.

[17]  C. Picado,et al.  Frequency and clinical characteristics of rapid-onset fatal and near-fatal asthma , 2002, European Respiratory Journal.

[18]  S. Rasmussen,et al.  Mortality associated with Down's syndrome in the USA from 1983 to 1997: a population-based study , 2002, The Lancet.

[19]  C R Smith,et al.  Sudden unexplained death in children with epilepsy , 2001, Neurology.

[20]  W. Barbaresi,et al.  Use and costs of medical care for children and adolescents with and without attention-deficit/hyperactivity disorder. , 2001, JAMA.

[21]  Suneel K. Gupta,et al.  Dose‐Proportional and Stereospecific Pharmacokinetics of Methylphenidate Delivered Using an Osmotic, Controlled‐Release Oral Delivery System , 2000, Journal of clinical pharmacology.

[22]  A. Lazarowski,et al.  Cerebral Arteritis Following Methylphenidate Use , 2000, Journal of child neurology.

[23]  I. Shoulson,et al.  Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children , 1999, Clinical pharmacology and therapeutics.

[24]  R. Shavelle,et al.  Causes of excess mortality in cerebral palsy , 1999, Developmental medicine and child neurology.

[25]  J. Manson,et al.  Obesity and mortality: a review of the epidemiologic data. , 1997, The American journal of clinical nutrition.

[26]  K. Neumärker Mortality and sudden death in anorexia nervosa. , 1997, The International journal of eating disorders.

[27]  R. Liberthson,et al.  Sudden death from cardiac causes in children and young adults. , 1996, The New England journal of medicine.

[28]  B. Lindsay,et al.  Impact of clinical history and electrophysiologic characterization of accessory pathways on management strategies to reduce sudden death among children with Wolff-Parkinson-White syndrome. , 1996, Journal of the American College of Cardiology.

[29]  N. Ryan,et al.  Another sudden death in a child treated with desipramine. , 1993, Journal of the American Academy of Child and Adolescent Psychiatry.

[30]  B. Birmaher,et al.  Sustained release methylphenidate: pharmacokinetic studies in ADDH males. , 1989, Journal of the American Academy of Child and Adolescent Psychiatry.

[31]  J. Trugman CEREBRAL ARTERITIS AND ORAL METHYLPHENIDATE , 1988, The Lancet.

[32]  J. Sorof,et al.  Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial , 2005, Pediatric Nephrology.

[33]  M. Wolraich,et al.  Pharmacokinetic Considerations in the Treatment of Attention-Deficit Hyperactivity Disorder with Methylphenidate , 2004, CNS drugs.

[34]  L. Magder,et al.  Psychotropic practice patterns for youth: a 10-year perspective. , 2003, Archives of pediatrics & adolescent medicine.

[35]  A. Hoes Case-control studies. , 1995, The Netherlands journal of medicine.